Recombinant multi-species Aggrecan/ACAN protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine Aggrecan/ACAN protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene is a member of the aggrecan/versican proteoglycan family. The encoded protein is an integral part of the extracellular matrix in cartilagenous tissue and it withstands compression in cartilage. Mutations in this gene may be involved in skeletal dysplasia and spinal degeneration. Multiple alternatively spliced transcript variants that encode different protein isoforms have been observed in this gene. [provided by RefSeq, Jul 2008]
The Alternative Names of target: ACAN,AGC1,AGCAN,Acan,Agc,Agc1,Aggrecan,Aggrecan core protein,CSPCP,CSPG1,CSPGCP,Cartilage-specific proteoglycan core protein (CSPCP),Chondroitin sulfate proteoglycan core protein 1 (Chondroitin sulfate proteoglycan 1),Cspg1,MSK16,SEDK,SSOAOD,b2b183Clo,cmd

Target products collectionGo to Aggrecan/ACAN products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0633-Ag-1/ GM-Tg-hg-SE0633-Ag-2 Human Aggrecan/ACAN protein Human
GM-Tg-rg-SE0633-Ag-1/ GM-Tg-rg-SE0633-Ag-2 Rat Aggrecan/ACAN protein Rat
GM-Tg-mg-SE0633-Ag-1/ GM-Tg-mg-SE0633-Ag-2 Mouse Aggrecan/ACAN protein Mouse
GM-Tg-cynog-SE0633-Ag-1/ GM-Tg-cynog-SE0633-Ag-2 Cynomolgus/Rhesus macaque Aggrecan/ACAN protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0633-Ag-1/ GM-Tg-felg-SE0633-Ag-2 Feline Aggrecan/ACAN protein Feline
GM-Tg-cang-SE0633-Ag-1/ GM-Tg-cang-SE0633-Ag-2 Canine Aggrecan/ACAN protein Canine
GM-Tg-bovg-SE0633-Ag-1/ GM-Tg-bovg-SE0633-Ag-2 Bovine Aggrecan/ACAN protein Bovine
GM-Tg-equg-SE0633-Ag-1/ GM-Tg-equg-SE0633-Ag-2 Equine Aggrecan/ACAN protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0633-Ag-1/ GM-Tg-hg-SE0633-Ag-2; GM-Tg-rg-SE0633-Ag-1/ GM-Tg-rg-SE0633-Ag-2;
GM-Tg-mg-SE0633-Ag-1/ GM-Tg-mg-SE0633-Ag-2; GM-Tg-cynog-SE0633-Ag-1/ GM-Tg-cynog-SE0633-Ag-2;
GM-Tg-felg-SE0633-Ag-1/ GM-Tg-felg-SE0633-Ag-2; GM-Tg-cang-SE0633-Ag-1/ GM-Tg-cang-SE0633-Ag-2;
GM-Tg-bovg-SE0633-Ag-1/ GM-Tg-bovg-SE0633-Ag-2; GM-Tg-equg-SE0633-Ag-1/ GM-Tg-equg-SE0633-Ag-2
Products Name Aggrecan/ACAN protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name Aggrecan/ACAN
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine Aggrecan/ACAN protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.